Log in or create an account for full access to this data.
Create a free account or log in to use this tool.
Create a free account or log in to explore DrugBank data.
MD05 is a beta-tricalcium phosphate (beta-TCP) coated with recombinant human growth/differentiation factor-5 (rhGDF-5).
- Mechanism
- Curator reviewed
MD05 has two components: the recombinant growth factor, rhGDF-5, a naturally occurring human protein that acts by promoting the growth of bone and the inorganic carrier, beta-Tricalcium phosphate (beta-TCP). Beta-TCP is a synthetic calcium phosphate biomaterial, which acts as a scaffold and space maintainer for new bone ingrowth. It is a well accepted biomaterial for bone augmentation in dentistry and orthopaedic surgery such as e.g. spinal fusion. Growth factor and carrier material are combined by Scil’s proprietary technology, which allows for a homogeneous distribution of the growth factor on the carrier and maintenance of structure and function of the protein and avoidance of its aggregation.
- Primary indication
- Investigated for use/treatment in periodontal disease.Curator reviewed
- Code names
- MD-05
Which companies are running trials of MD05, in which indications and phases, and which of those programs are still active?